Ben Venue Laboratories Inc – FDA 483, May 25, 2011

During an FDA inspection from May 2-25, 2011, pharmaceutical manufacturer Ben Venue Laboratories, Inc., was cited for significant objectionable conditions related to its compliance with Current Good Manufacturing Practices (cGMP). The main violations included a lack of adequate Quality Unit oversight in approving products and procedures. Critical issues in contamination control were observed, such as recurring foreign material (stainless steel/iron particles) in manufactured products, with no identified root cause or corrective actions for nine complaints spanning several years. Furthermore, deficiencies in aseptic processing were noted, including media fills being accepted despite not meeting minimum protocol requirements and inadequate evaluation of manual interventions. The firm also exhibited widespread environmental control failures, stemming from compromised cleanroom infrastructure, insufficient air flow pattern evaluations, and an environmental monitoring program that failed to investigate over 1,100 microbial contaminants and numerous non-viable particulate excursions. Sterility failures were linked to unsterilized gloves and uninvestigated anaerobic contamination. The company must implement comprehensive corrective and preventative actions to address these systemic issues, ensuring enhanced quality oversight, improved contamination control, validated aseptic processes, and robust environmental monitoring to meet regulatory standards.